Why the study?
Human albumin fusion technology was developed to increase the in-vivo half-life and invoke less immune response for purified streptokinase.
Answers are grounded in this paper and cite their sources.
The successful in vitro development and purification of an HSA-SK fusion protein demonstrates retained biological activity, offering a potential foundation for thrombolytic therapies with extended half-lives and reduced immunogenicity.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nan et al. (2022) studied this question. HSA-SK fusion protein was evaluated on Protein expression, purity, and yield.
Synapse has enriched 10 related papers. Consider them for comparative context: